Newron Shares Face Pressure Following Sharp Financial Reversal

Newron swings to a €13.2M net loss in 2025 due to a sharp drop in licensing revenue, but strong liquidity funds operations through 2027. Stock down ~39% YTD.

Pharmaceutical firm Newron SpA has reported a significant financial downturn for 2025, swinging from a net profit of €15.8 million the previous year to a net loss of €13.2 million. This reversal has placed considerable pressure on the company's stock price.

A Shift in Financial Fortunes

The primary driver behind this loss is a steep decline in licensing revenue, which plummeted from €44.5 million in 2024 to just €8.6 million in 2025. Concurrently, the company increased its investment in research and development, with expenditures rising from €13.6 million to €15.1 million. This indicates a continued commitment to its development pipeline despite the lack of immediate corresponding income.

Market reaction was swift, with shares declining on both of its trading venues. Since the start of the year, the stock has shed approximately 39 percent of its value and is currently trading well below its 50-day moving average.

Liquidity Position Provides a Runway

Despite the annual loss, Newron's financial standing is not precarious. The company ended the year with liquid funds of €28.9 million, a substantial increase from the €9.8 million reported at the beginning of the period. This position is further bolstered by €15 million raised through a capital increase in February 2026 and an additional €11 million expected before year-end from an existing financing agreement. Management states this liquidity secures its development programs and ongoing operations through 2027.

The company's strategic focus remains on its Phase III ENIGMA-TRS program for Evenamide, a candidate treatment for therapy-resistant schizophrenia. Pivotal data from this trial is anticipated in the fourth quarter of 2026. These results are likely to be a critical factor in how investors reassess Newron's long-term prospects.